公开(公告)号：US20220175814A1

公开(公告)日：2022-06-09

申请号：US17594054

申请日：2020-04-03

申请人： TARGIMMUNE THERAPEUTICS AG

发明人： Derrick BROKA ,  David COLECCHIA ,  Lucia D'AMICO ,  Eric KITAS ,  Alexander LEVITZKI ,  Esteban POMBO-VILLAR ,  Alexei SHIR ,  Maya ZIGLER ,  Davor BAJIC ,  Anita JARZEBINSKA

IPC分类号： A61K31/713 ,  A61K47/60 ,  A61K47/64 ,  A61P35/00 ,  C07K16/28 ,  C07K16/32 ,  C07K17/06

摘要： The present invention relates to a kit-of-parts comprising and a composition comprising a polyplex comprising a double stranded RNA (dsRNA) and a polymeric conjugate comprising a polyethyleneimine (PEI), one or more polyethylene glycol (PEG) moieties and one or more targeting moieties, and wherein each of said one or more targeting moieties is capable of binding to a cancer antigen; and at least one antibody, wherein said at least one antibody is capable of modulating an immune checkpoint protein. Further the invention relates to this composition or kit-of-parts for use in the treatment of cancer.

公开(公告)号：US20240033364A1

公开(公告)日：2024-02-01

申请号：US18316828

申请日：2023-05-12

申请人： TARGIMMUNE THERAPEUTICS AG

发明人： Esteban POMBO-VILLAR ,  Alexander LEVITZKI ,  Yael LANGUT ,  Maya ZIGLER ,  Alexei SHIR ,  Eric KITAS

IPC分类号： A61K47/54 ,  A61K47/65 ,  A61K47/60 ,  A61K47/59 ,  C07K7/02 ,  C07K7/06

CPC分类号： A61K47/549 ,  A61K47/65 ,  A61K47/60 ,  A61K47/59 ,  C07K7/02 ,  C07K7/06

摘要： The present invention relates to a polyplex for use in the treatment of castration resistant prostate cancer (CRPC) comprising a double stranded RNA (dsRNA) and a polymeric conjugate, wherein said polymeric conjugate consists of a linear polyethyleneimine (LPEI), one or more polyethylene glycol (PEG) moieties, one or more linkers and one or more targeting moieties, wherein said LPEI is covalently bound to one or more PEG moieties and each of said one or more PEG moieties is conjugated via one of the one or more linkers to one of the one or more targeting moieties, wherein each of said one or more targeting moieties is capable of binding to a cancer antigen, and wherein said cancer antigen is prostate surface membrane antigen (PSMA). Further, the invention relates to a pharmaceutical composition for use in the treatment of CRPC.

公开(公告)号：US20200230248A1

公开(公告)日：2020-07-23

申请号：US16650980

申请日：2018-09-27

申请人： TARGIMMUNE THERAPEUTICS AG

发明人： Esteban POMBO-VILLAR ,  Alexander LEVITZKI ,  Yael LANGUT ,  Maya ZIGLER ,  Alexei SHIR ,  Eric KITAS

IPC分类号： A61K47/54 ,  A61K47/65 ,  A61K47/60 ,  A61K47/59

摘要： The present invention relates to a polyplex for use in the treatment of castration resistant prostate cancer (CRPC) comprising a double stranded RNA (dsRNA) and a polymeric conjugate, wherein said polymeric conjugate consists of a linear polyethyleneimine (LPEl), one or more polyethylene glycol (PEG) moieties, one or more linkers and one or more targeting moieties, wherein said LPEl is covalently bound to one or more PEG moieties and each of said one or more PEG moieties is conjugated via one of the one or more linkers to one of the one or more targeting moieties, wherein each of said one or more targeting moieties is capable of binding to a cancer antigen, and wherein said cancer antigen is prostate surface membrane antigen (PSMA). Further, the invention relates to a pharmaceutical composition for use in the treatment of CRPC.